WO2012051941A1 - 15-苄亚基-14-脱氧-11,12-脱氢穿心莲内酯衍生物在制备药物中的用途 - Google Patents
15-苄亚基-14-脱氧-11,12-脱氢穿心莲内酯衍生物在制备药物中的用途 Download PDFInfo
- Publication number
- WO2012051941A1 WO2012051941A1 PCT/CN2011/080966 CN2011080966W WO2012051941A1 WO 2012051941 A1 WO2012051941 A1 WO 2012051941A1 CN 2011080966 W CN2011080966 W CN 2011080966W WO 2012051941 A1 WO2012051941 A1 WO 2012051941A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- preparation
- tumor
- cancer
- compound
- andrographolide
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/32—Oxygen atoms
- C07D307/33—Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
Definitions
- the invention relates to the pharmaceutical use of andrographolide derivatives, in particular to the compound 15-benzylidene-14-deoxy- 11, 12-dehydroandrographolide derivatives and 3, 19 esterified compounds thereof, belonging to the technical field of medicine.
- Andrographolide is a diterpene lactone compound extracted from Andrographis paniculata (Burm. f.) Nees, which is one of the main active ingredients of Chinese herbal medicine Andrographis paniculata. It has antipyretic and anti-inflammatory properties. Antibacterial, anti-viral, anti-tumor and other effects. In the field of anti-tumor, the existing research work mainly focuses on improving cytotoxic activity through structural modification and elucidating the mechanism of apoptosis induced by andrographolide. Radi Labs Ltd.
- a pharmaceutical composition containing "triacetyl andrographolide and its medical use” (CN101129354), which is filed by Han Guang, relates to a pharmaceutical composition containing triacetyl andrographolide as an active ingredient and a pharmaceutically acceptable carrier. And its use in the preparation of anti-inflammatory, immunosuppressive and anti-tumor drugs.
- Hutchison Whampoa Pharmaceutical Co., Ltd. applied for the medical use of andrographolide and its derivatives and analogues (CN1666985), involving the preparation of TNF-ct and/or IL-1 ⁇ Use in inhibitors.
- the object of the present invention is to provide a 15-benzylidene-14-deoxy-11, 12-dehydroandrographolide derivative and a 3,19 ester thereof for use in the preparation of an antitumor drug.
- the compound of the present invention has the structure shown in Formula 1,
- Formula 1 is hydrogen; R 2 is phenyl, p-methoxyphenyl or halophenyl; R 3 and R 4 are each hydrogen or C0R 5 , and R 5 is 3-pyridyl or CH 2 CH 2 C00H.
- Preferred compounds are hydrogen; R 2 is phenyl, p-methoxyphenyl, p-fluorophenyl, p-chlorophenyl, p-bromophenyl, 3-fluorophenyl, 3-chlorophenyl or 3-bromophenyl; each of R 3 and R 4 is hydrogen.
- R 2 is phenyl, p-methoxyphenyl, p-fluorophenyl, p-chlorophenyl, p-bromophenyl, 3-fluorophenyl, 3-chlorophenyl or 3-bromobenzene
- the above-mentioned compound proposed by the present invention has been prepared by the invention patent CN: 200510107247.
- 14-deoxy-11,12-dehydroandrographolide or 14-deoxygenation One of -11,12-dehydro-3,19-esterified andrographolide is dissolved in methanol or ethanol or tetrahydrofuran under different conditions, and heated at a temperature of 15 to 70 ° C under base catalysis.
- An andrographolide derivative represented by Formula 1 can be obtained.
- the base used therein is one of sodium carbonate, potassium carbonate, potassium hydrogencarbonate, sodium hydrogencarbonate, triethylamine, pyridine, hydrazine, hydrazine-dimethylaminopyridine; and the amount thereof is 0.2 to 5% by mole.
- the aldehyde used is an aromatic aldehyde, preferably benzaldehyde, halogenated benzaldehyde, etc., more preferably benzaldehyde, p-fluorobenzaldehyde, p-chlorobenzaldehyde, p-bromobenzaldehyde, p-methoxybenzaldehyde; 14-deoxy-11,
- the 12-dehydro-3,19-esterified andrographolide corresponds to the formula 1 in which R 3 and R 4 are each COR 5 and R 5 is 3-pyridyl or CH 2 CH 2 COOH.
- a plate cloning assay was used to study the inhibitory effect of the above compounds on the formation of tumor cell clones; the anti-tumor cell migration of the compounds was studied by the scratch damage method; the compounds were studied by the scratch damage method and the Transwell chamber method. Inhibition of migration of human vascular endothelial cells ECV304. Further, using Compounds 2 and 3 as an example, H22 mouse transplanted tumor model was used to study its anti-tumor effect and anti-tumor angiogenesis; ⁇ S180 sarcoma mouse xenograft model was used to study the anti-tumor effect and anti-invasive metastasis of compounds 2 and 3. effect.
- the anti-metastatic effect of the compounds was studied using the mouse melanoma B16-F10 lung metastasis model. As a result, it was confirmed that the above compound has an exact antitumor effect and can be used as an active ingredient for the preparation of a drug against gastric cancer, lung cancer, cervical cancer, bladder cancer, esophageal cancer, colon cancer, liver cancer, prostate cancer, and melanoma.
- the compounds of the present invention were confirmed to have little toxicity by a limited toxicity test in mice by using Compounds 2 and 3.
- the compound is used as an effective medicinal ingredient or combined with other drugs, and is prepared for anti-tumor oral administration according to various conventional pharmaceutical methods and process requirements, and mixed with auxiliary and/or added ingredients which are acceptable in the pharmaceutical industry.
- the oral preparation is a tablet, a pill, a capsule, a granule or a syrup; the injectable preparation includes an injection or a lyophilized powder dosage form.
- Figure A shows the inhibitory activity of two-dimensional migration of Eca-109 cells (24h)
- B is the inhibitory activity of two-dimensional migration of HT29 cells (24h.)
- C is the inhibitory activity of two-dimensional migration of 5637 cells (24h).
- Figure D is the inhibitory activity of human gastric adenocarcinoma SGC-7901 cells in two-dimensional migration (36h)
- E is the inhibitory activity of human non-small cell lung cancer A549 cells in two-dimensional migration (36h)
- F picture is for human prostate Inhibitory activity of two-dimensional migration of cancer PC-3 cells (36 h).
- FIG. 3 shows changes in body weight of each group before and after administration (24d) of the compound 3 of the present invention.
- Cell line Human gastric adenocarcinoma SGC-7901 cell line, human non-small cell lung cancer A549 cell line and human cervical cancer Hela cell line was purchased from the Cell Resource Center of Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences.
- RPMI1640 medium, DMEM high sugar medium and trypsin are all GIBICO products.
- Standard fetal bovine serum (FBS) was purchased from Tianjin Haoyang Biological Products Technology Co., Ltd.; no mycoplasma fetal bovine serum (FCS), purchased from Hangzhou Sijiqing Bioengineering Materials Co., Ltd.
- Andrographolide (1) is provided by Furen Pharmaceutical Group Co., Ltd.
- the andrographolide derivative synthesized by the present invention is provided by Zhengzhou University New Drug Research and Development Center.
- the CB150 type C0 2 incubator is produced by Binder, Germany; the TS100-F-PH type inverted microscope is produced by Nikon Corporation of Japan.
- Cell culture plates were purchased from Costar Corporation of the United States.
- Experimental method A plate colony formation method was used. The cells with good growth state were prepared, and the cell suspension was prepared and seeded on a 6-well culture plate. The number of cells was 100/well, and the drug-containing medium was added to 10 mL/well to make the final concentration of the compound 0, 1.25, 2.50, respectively. 5.00, 7.50, ⁇ . ⁇ /L, set the two plates in parallel. The cells were placed in a C0 2 incubator and cultured at 37 ° C, 5% CO 2 and saturated humidity for 2 weeks.
- the inhibitory activities of the compounds of the present invention on the formation of A549, SGC-79.01 and Hela cell clones are shown in Table 1.
- the results show that the present invention relates to a compound having a remarkable anti-tumor cell cloning effect.
- compounds 2, 5, 6 and 7 inhibited the cloning of these three tumor cells compared with andrographolide (1), and the inhibition of the formation of A549 and SGC-7901 by compound 4 was inhibited.
- the effect is also significantly higher than that of andrographolide (1).
- Cell line human bladder cancer 5637 cell line, human esophageal cancer Eca-109 cell line, human colon cancer HT29 cell line, human gastric cancer gland SGC-7901 cell line, human non-small cell lung cancer A549 cell line and prostate cancer PC-
- the 3 cell line was purchased from the Cell Resource Center of the Shanghai Institute of Biological Sciences, Chinese Academy of Sciences.
- the inhibitory activity of the compound of the present invention 2-8 on the two-dimensional migration of tumor cells is shown in Fig. 1.
- the results showed that this compound had obvious anti-tumor cell migration.
- the compound 2-8 of the present invention has significant inhibitory effects on the two-dimensional migration of tumor cells Eca-109, HT29, 5637, SGC-7901, A549 and PC-3; wherein compound 2 acts on 5637 and SGC-7901 Stronger, compounds 3, 5, 8 have stronger effects on A549 and Eca-109, compounds 4 and 6 have stronger effects on 5637 and PC-3, and compound 7 has stronger effects on 5637 and A549.
- Andrographolide (1) has a stronger effect on 5637 and A549.
- the serum-free medium was first added to the upper and lower chambers of the Transwell chamber, and placed in a 37 ° C incubator for 1 h; the cultured to 80-90% of human vascular endothelial cells ECV304 (purchased from the Chinese Academy of Sciences' Type Culture Collection) Resuspend in medium containing 10% fetal bovine serum, adjust the cell concentration to lxlOVmL; remove the medium in the upper and lower chambers of Transwell chamber, add the above cell liquid to the upper chamber, 100 ⁇ !
- Cyclophosphamide was produced by Tianjin Jinshi Pharmaceutical Co., Ltd. (Approval No.: National Pharmaceutical Standard H12021006); Mingjiao and Carmine were produced by Sigma; other reagents were of commercially available analytical grade.
- the drug was formulated into a 0.5% CMC-Na solution and was solubilized with Tween-80 (final concentration 0.1%).
- the 10% (w/v) carmine solution was prepared with a salt solution containing 5% (w/v) gelatin before use.
- the salt solution of 5% (w/v) gelatin was prepared with physiological saline.
- the remaining drugs, reagents and their preparations are the same as the examples.
- mice hepatoma cells H22 were passaged for 7 days in vivo, diluted with physiological saline to a concentration of l X 107 mL, and inoculated into the right forelimb of the mouse, 0.2 nL/only, randomly divided into groups of 12 animals. After inoculation of tumor cells for 24 hours, daily intragastric administration was started, 0. 2 m L/10 g body weight, and continuous administration for 7 days. Fasting for 8 hours after the last dose (not allowed for water).
- mice 1% pentobarbital sodium (80mg/kg) anesthetized animals
- blank control group mice were injected intravenously with 5% (w/v) gelatin in 40°C salt solution 1mL, and the remaining groups of mice were injected with tail vein 10 % (W/V) carmine, 5% (W/V) gelatin in 40 ° C salt solution 1 mL, the mice were frozen at -20 ° C for 2 h to make the gelatin solidified.
- the tumor tissue was isolated and weighed. Homogenize with 3M Na0H (10fflL/g tumor weight). After centrifugation at 14,000 rpm for 20 min, the supernatant was taken, and the absorbance value was measured at a wavelength of 490 ⁇ .
- the carmine content was calculated according to the carmine standard curve, and the experimental results were expressed by the tumor inhibition rate and the vascular index.
- the data were processed by SPSS17.0 statistical software, and the data were expressed by the mean standard deviation (s), and the significance test was performed by t test. PO.05 was statistically significant.
- Tumor inhibition rate (%) (model group tumor weight one administration group tumor weight) / model group tumor weight X 100%; vascular index (VI, nig / g) ⁇ carmine content / tumor weight in tumor tissue. .
- the blood vessel index of the model group was 4.82 ⁇ 2. 43, positive control group (ring Phosphoryl 20 mg/kg) and Compound 1 (1.35 ramol/kg) showed no significant inhibition of angiogenesis.
- the vascular index of the tumor tissues of the low (0.65 mmol/kg), medium (1.0 mmol/kg), high (1. 35 mmol/kg) doses decreased in different degrees, and the middle dose group inhibited.
- the angiogenesis effect is stronger than the low dose group and the high dose group.
- Compound 2 showed a dose-dependent decrease in vascular index over the experimental dose range. Therefore, Compounds 2 and 3 significantly inhibited H22 tumor growth and inhibited angiogenesis.
- the model group I and the compound 1 and group 3 of the present invention were inoculated in the first batch, and the normal group, the model group II, the cyclophosphamide group and the compound 2 group of the present invention were inoculated in the second batch.
- Tumor inhibition rate (%) (1 - mean tumor index of the administration group / mean tumor index of the model group) X 100%.
- RPMI1640 medium was resuspended, centrifuged at lOOOr.pm for 5 min, the supernatant was discarded, and a single cell suspension (10 7 /mL) was prepared by adding sterile PBS.
- Each C57 mouse was injected with 0.2 mL in the tail vein, and the body weight of the experimental mice was randomized. Divided into 4 groups, respectively, model control group, cyclophosphamide group G0mg/kg), compound 3 low dose group (0.85mmol/kg), compound 3 high dose group (l.lmmol/kg), 5 rats in each group.
- the cells were intragastrically administered 24 hours after the cells were inoculated, administered continuously for 24 days, and the body weight of the mice was recorded daily.
- TNF-ot and IL- ⁇ were determined by enzyme-linked immunosorbent assay according to the kit instructions. The data were processed by SPSS17.0 statistical software, and the data were expressed as mean ⁇ standard deviation (s), and the significance test was performed by t test. PO.05 was statistically significant.
- Tumor metastasis inhibition rate (%) (number of average nodules in the model group - average number of nodules in the administration group) The average number of nodules in the I model group was ⁇ %.
- mice 3 ⁇ 4" changes in body weight before and after administration (24d) in C57 mice (Fig. 3), •
- the increase in body weight of mice in the cyclophosphamide group was found to be minimal (average 0.7 g), lower than the model group (mean '2.1g), but the difference did not reach a significant level, suggesting that cyclophosphamide may have some toxic side effects; compound 3' low (0.85mmol/kg), 'high (110mmol/kg) dose group mice average body weight
- the weight gains were 1.64g and 2.00g, respectively, and the difference from the model group was not statistically significant (P>G.05).
- TNF- ⁇ and IL- ⁇ in the serum of mice are shown in Table 6.
- Administration of low dose (0.85 mmol/kg) and high dose (1.1 mmol/kg) of compound 3 down-regulated the expression of IL- ⁇ , and the difference between the high-dose group and the model group reached a significant level (PO.05).
- the dose of compound 3 was 0.85mmol/kg, the expression of TNF-a in the serum of mice was significantly inhibited. Compared with the model group, the difference was statistically significant (P ⁇ 0.05).
- mice weighing 20 ⁇ 2g, half male and half female, were randomly divided into groups of 10 each. After the animals were fasted for 12 hours (not limited to drinking water), the compounds of the present invention 2 and 3 were administered at a dose of 5.00 g/kg once by gavage. Observe and record the poisoning performance of the animals. Weigh once a day. After continuous observation for 14 days, the results are shown in Table 7.
- mice showed no obvious poisoning and did not die, indicating that the acute toxicity of compounds 2 and 3 was very small, and it was used for the preparation of antitumor drugs, which has high practical and developmental value.
- Table 7 Acute toxicity test of compounds 2 and 3 of the present invention
- the derivatives have clear anti-tumor activity, high efficiency and low toxicity, and have the potential to be developed as anti-tumor drugs, which can be used for the treatment and prevention of tumor metastasis.
- the compounds used in the above experiments were identical in number, and the number 1 was andrographolide, and the numbers 2 to 8 were the compounds of the present invention.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/823,841 US9198894B2 (en) | 2010-10-22 | 2011-10-19 | Uses of 15-benzylidene-14-deoxy-11,12-didehydroandrographolide derivatives in the preparation of antineoplastic drugs |
JP2013534154A JP5837935B2 (ja) | 2010-10-22 | 2011-10-19 | 医薬品の調製のための15−ベンジリデン−14−デオキシ−11,12−ジデヒドロアンドログラホリド誘導体の使用 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201010516322.3 | 2010-10-22 | ||
CN2010105163223A CN101972247B (zh) | 2010-10-22 | 2010-10-22 | 15-苄亚基-14-脱氧-11,12-脱氢穿心莲内酯衍生物的药物用途 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2012051941A1 true WO2012051941A1 (zh) | 2012-04-26 |
Family
ID=43572177
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2011/080966 WO2012051941A1 (zh) | 2010-10-22 | 2011-10-19 | 15-苄亚基-14-脱氧-11,12-脱氢穿心莲内酯衍生物在制备药物中的用途 |
Country Status (4)
Country | Link |
---|---|
US (1) | US9198894B2 (zh) |
JP (1) | JP5837935B2 (zh) |
CN (1) | CN101972247B (zh) |
WO (1) | WO2012051941A1 (zh) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101972247B (zh) * | 2010-10-22 | 2012-06-06 | 郑州大学 | 15-苄亚基-14-脱氧-11,12-脱氢穿心莲内酯衍生物的药物用途 |
CN102302487B (zh) * | 2011-07-04 | 2013-04-10 | 郑州大学 | 穿心莲内酯c15位取代系列衍生物在制备抗乙型肝炎药物中的应用 |
CN102838571B (zh) * | 2012-09-25 | 2014-12-03 | 郑州大学 | 含γ-亚基丁烯内酯穿心莲内酯衍生物、其合成方法和用途 |
WO2018177301A1 (zh) * | 2017-04-01 | 2018-10-04 | 郑州大学 | 15-亚基-14-脱氧-11,12-脱氢穿心莲内酯衍生物及其在制备抗纤维化药物中的应用 |
CN108690860A (zh) * | 2017-04-09 | 2018-10-23 | 勤浩医药(苏州)有限公司 | 一种快速筛选抗肿瘤特异性靶点药物的方法 |
CN109796429B (zh) * | 2018-03-02 | 2023-04-11 | 郑州大学 | 穿心莲内酯十氢萘结构修饰衍生物系列iii及其制备方法和用途 |
CN109851602B (zh) * | 2018-03-02 | 2023-04-11 | 郑州大学 | 14-脱氧-11,12-脱氢-8,12-环氧-穿心莲内酯及其15位取代衍生物 |
CN111689934B (zh) * | 2020-06-24 | 2022-08-02 | 郑州大学 | 14-脱羟-13-脱氢穿心莲内酯-12-磺酸钾的单晶体及制备方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1978437A (zh) * | 2005-12-07 | 2007-06-13 | 郑州大学 | 穿心莲内酯c15位取代系列衍生物及其制备方法 |
CN101972247A (zh) * | 2010-10-22 | 2011-02-16 | 郑州大学 | 15-苄亚基-14-脱氧-11,12-脱氢穿心莲内酯衍生物的药物用途 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6486196B2 (en) * | 2000-05-05 | 2002-11-26 | Dr. Reddy's Research Foundation | Anticancer compounds: process for their preparation and pharmaceutical compositions containing them |
CN100999520B (zh) * | 2007-01-05 | 2010-12-01 | 郑州大学 | 异穿心莲内酯类似物及其制备方法 |
CN100528894C (zh) * | 2007-01-05 | 2009-08-19 | 郑州大学 | 15-(14-脱氧-11,12-脱氢)-穿心莲内酯碳苷衍生物及其制备方法 |
KR101325374B1 (ko) * | 2008-02-19 | 2013-11-08 | 가부시키가이샤 오츠까 세이야꾸 고죠 | 신체 기능의 회복에 유용한 경구 또는 경장 조성물 |
CN101416959B (zh) * | 2008-12-15 | 2010-11-10 | 郑州大学 | 15-亚甲基取代穿心莲内酯衍生物在制备抗炎解热镇痛药物中的用途 |
CN101416958B (zh) * | 2008-12-15 | 2010-12-22 | 郑州大学 | 15-亚甲基取代穿心莲内酯衍生物在制备抗乙型肝炎药物中的用途 |
-
2010
- 2010-10-22 CN CN2010105163223A patent/CN101972247B/zh active Active
-
2011
- 2011-10-19 WO PCT/CN2011/080966 patent/WO2012051941A1/zh active Application Filing
- 2011-10-19 US US13/823,841 patent/US9198894B2/en active Active
- 2011-10-19 JP JP2013534154A patent/JP5837935B2/ja active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1978437A (zh) * | 2005-12-07 | 2007-06-13 | 郑州大学 | 穿心莲内酯c15位取代系列衍生物及其制备方法 |
CN101972247A (zh) * | 2010-10-22 | 2011-02-16 | 郑州大学 | 15-苄亚基-14-脱氧-11,12-脱氢穿心莲内酯衍生物的药物用途 |
Non-Patent Citations (2)
Title |
---|
DAI GUIFU ET AL.: "The in vitro anti-tumor activities of andrographolide derivatives and the structure-activity relationships.", CHINESE JOURNAL OF NEW DRUGS., vol. 20, no. IS.4, 28 February 2011 (2011-02-28), pages 362 - 366 * |
XU HAIWEI ET AL.: "Synthesis of andrographolide derivatives: A new family of a-glucosidase inhibitors.", BIOORGANIC & MEDICINAL CHEMISTRY., vol. 15, no. 12, 2007, pages 4247 - 4255 * |
Also Published As
Publication number | Publication date |
---|---|
JP2013544789A (ja) | 2013-12-19 |
JP5837935B2 (ja) | 2015-12-24 |
CN101972247A (zh) | 2011-02-16 |
CN101972247B (zh) | 2012-06-06 |
US20130237596A1 (en) | 2013-09-12 |
US9198894B2 (en) | 2015-12-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2012051941A1 (zh) | 15-苄亚基-14-脱氧-11,12-脱氢穿心莲内酯衍生物在制备药物中的用途 | |
CN101045046B (zh) | 巴西苏木素类化合物在制备抗肿瘤药物中的用途 | |
CN102018698A (zh) | 治疗雌激素受体相关疾病的化合物及其方法 | |
TWI547277B (zh) | Honokiol for the treatment or prevention of bladder cancer growth and metastasis and improve the cachexia new use | |
Liu et al. | Synthesis of thioether andrographolide derivatives and their inhibitory effect against cancer cells | |
WO2011131102A1 (zh) | 含笑内酯的制备方法及其用途 | |
CN109453183B (zh) | 香蜂草苷的肿瘤多药耐药逆转剂或抗肿瘤药物增敏剂及其应用 | |
JPH1121284A (ja) | フラノナフトキノン誘導体及びこれを含有する医薬 | |
CN104844617B (zh) | 鸦胆苦醇衍生物及其在炎症和免疫功能紊乱疾病中的用途 | |
CN105037429A (zh) | 一种鬼臼毒素类磷脂化合物、其药物组合物及应用 | |
CN103420963B (zh) | 木香烃内酯衍生物,其药物组合物及其制备方法和用途 | |
CN114805470A (zh) | 一种偏诺皂苷元-精氨酸衍生物及其制备方法和在制备抗非小细胞肺癌药物中的用途 | |
CN101317835B (zh) | 斑蝥素及其衍生物在制备肿瘤化疗增敏药物中的应用 | |
WO2014169697A1 (zh) | 长春碱类衍生物及其制备方法和应用 | |
CN111821303B (zh) | 沃替西汀及其盐在制备抗肿瘤药物中的应用 | |
CN109897022A (zh) | 含笑内酯衍生物、其药物组合物及其制备方法和用途 | |
CN104744518B (zh) | 金属钌配合物及其制备方法和应用 | |
CN107362158B (zh) | 马钱苷元在制备抗肿瘤药物中的用途 | |
CN107325031B (zh) | 一种含硒二苯甲酮及其衍生物和制备方法以及在制备抗肿瘤药物中的应用 | |
CN111606917A (zh) | 一种具c环骈合内酯环新颖骨架的松香烷类化合物及其制备方法与应用 | |
CN115558012B (zh) | 一种薯蓣皂苷元-丹参素衍生物及其自组装纳米颗粒和制备方法及用途 | |
CN108164476B (zh) | 间苯二腈类化合物、其应用以及包含该化合物的药物 | |
CN101786952B (zh) | 一种蒽醌类化合物及其赖氨酸盐的制备方法及医药用途 | |
CN109730992A (zh) | 一种噻喃酮类化合物在制备抗肿瘤药物中的应用 | |
CN105477068B (zh) | 一种桑枝叶活性部位的制备方法及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11833847 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2013534154 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13823841 Country of ref document: US |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 11833847 Country of ref document: EP Kind code of ref document: A1 |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A) DATED 09/12/2013) |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 09.12.2014) |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 11833847 Country of ref document: EP Kind code of ref document: A1 |